新疆医科大学学报

参考文献

[1]胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J].中国循环杂志, 2019, 34(3):209-220.

[2]刘芳超顾东风.中国心血管病防治的过去、现在和未来[J].中国心血管病防治, 2020, 20(1):2-4,17.

[3] TILSTAM P V, QI D, LENG L, et al. MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics[J]. Expert Opin Ther Targets, 2017, 21(7):671-683.

[4]邓湘宁,王新宇,于海奕,等.急性心肌梗死患者血巨噬细胞移动抑制因子的变化及临床意义[J].中国心血管杂志,2018,23(2):104-109.

[5]邓湘宁,王新宇,高炜.巨噬细胞移动抑制因子—心肌缺血/再灌注损伤的诊疗新靶点[J].中国介入心脏病学杂志,2019,27(8):470-473.

[6] BAUGH J A, CHITNIS S, DONNELLY S C, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor(MIF)gene associated with disease severity in rheumatoid arthritis[J]. Genes Immunity, 2002, 3(3):170-176.

[7] AWANDARE G A, MARTINSON J J, WERE T, et al. MIF(macrophage migration inhibitory factor)promoter polymorphisms and susceptibility to severe malarial anemia[J]. The Journal of infectious diseases, 2009, 200(4):629-637.

[8] SANTOSCOY-ASCENCIO G, BANOS-HERNANDEZ C J, NAVARRO-ZARZA JE, et al. Macrophage migration inhibitory factor promoter polymorphisms are associated with disease activity in rheumatoid arthritis patients from Southern Mexico[J]. Mol Genet Genomic Med, 2020, 8(1):1037-1039.

[9] FALVEY J D, BENTLEY R W, MERRIMAN T R, et al. Macrophage migration inhibitory factor gene polymorphisms in inflammatory bowel disease:an association study in New Zealand Caucasians and meta-analysis[J]. World Gastroenterol, 2013, 19(39):6656-6664.

[10] HERDER C, LLLIG T, BAUMERT J, et al. Macrophage migration inhibitory factor(MIF)and risk for coronary heart disease:results from the MONICA/KORA Augsburg case-cohort study, 1984-2002[J]. Atherosclerosis, 2003,29(2):380-388.

[11] VALDES-ALVARADO E, MUNOZ-VALLE J F, VALLE Y, et al.Association between the-794(CATT)5-8 MIF gene polymorphism and susceptibility to acute coronary syndrome in a western Mexican population[J]. Immunol Res, 2014, 27(4)854-860.

[12] LUO J Y, XU R, LI X M, et al. MIF gene polymorphism rs755622is associated with coronary artery disease and severity of coronary lesions in a Chinese kazakh population:a case-control study[J].Medicine(Baltimore), 2016,95(4):2617.

[13] COBAN N,ERKAN A F,EKICI B,et.al.Macrophage migration inhibitory factor(MIF)gene-173 G>C polymorphism and its relationship to coronary artery disease and type 2 diabetes[J].Turk Kardiyol Dern Ars,2019,47(1):29-37.

[14]王玉苹．MIF-rs1007888位点单核苷酸基因多态性与妊娠期糖尿病的相关性研究[D].青岛:青岛大学, 2013.

[15] NISHIHIRA J, SAKAUE S. Overview of macrophage migration inhibitory factor(MIF)as a potential biomarker relevant to adiposity[J]. Tradit Complement Med, 2012,2(3):186-191.

[16] SANDOVAL D A, D'ALESSIO D A. Physiology of proglucagon peptides:role of glucagon and GLP-1 in health and disease[J]. Physiol Rev, 2015, 95(2):513-548.

[17] HELMSTADTER J, FRENIS K, FILIPPOU K, et al. Endothelial GLP-1(Glucagon-Like Peptide-1)receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension[J]. Arterioscler Thromb Vasc Biol, 2020, 40(1):145-158.

[18] PAN X, XU Q, CHEN J, et al. Preliminary evaluation of 18F-AlFNOTA-MAL-Cys40-Exendin-4 in rodent heart after myocardial ischemia and reperfusion[J]. Mol Med Rep,2019,20(3):2276-2284.

[19] FEI Y, TSOI M F, CHEUNG B M Y. Cardiovascular outcomes in trials of new antidiabetic drug classes:a network meta-analysis[J].Cardiovasc Diabetol, 2019, 18(1):112-115.

[20] YU M, WANG K, LIU H, et al. GLP1R variant is associated with response to exenatide in overweight Chinese Type 2 diabetes patients[J]. Pharmacogenomics, 2019, 20(4):273-277.

[21] SCOTT R A, FREITAG D F, LI L, et al. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease[J]. Sci Transl Med,2016,28(6):341-347.

[22] HAN E, PARK H S, KWON O, et al. A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type2 diabetes[J]. Medicine(Balt imore), 2016, 95(44):e5155.

[23]苏日拉,郭瑞芳. CCN1/Cyr61基因的生物学功能及在炎症性反应中的作用[J].内蒙古医科大学学报, 2013, 35(5):407-416.

[24] LEE S, AHAD A, LUU M, et al. CCN1-Yes-Associated Protein Feedback Loop Regulates Physiological and Pathological Angiogenesis[J]. Mol Cell Bio, 2019, 39(18).

[25] PERROT A, SCHMITT K R, ROTH E M G, et al. CCN1 mutation is associated with atrial septal defect[J]. Pediatr Cardiol, 2015, 36(2):295-299.

[26] MO F E, LAU L F. The matricellular protein CCN1 is essential for cardiac development[J]. Circ Res, 2006, 99(9):961-969.

[27] PLANCK T, SHAHIDA B, SJOGREN M, et al. Association of BTG2, CYR61, ZFP36, and SCD gene polymorphisms with Graves'disease and ophthalmopathy[J]. Thyroid, 2014, 24(7):1156-1161.

[28] BOUCHARD L, TCHERNOF A, DESHAIES Y, et al. CYR61 polymorphisms are associated with plasma HDL-cholesterol levels in obese individuals[J]. Clin Genet, 2007, 72(3):224-229.

[29] YU P L, WANG C, LI W, et al. Visfatin level and the risk of hypertension and cerebrovascular accident:a systematic review and meta-analysis[J]. Horm Metab Res, 2019, 51(4):220-229.

[30] KADOGLOU N P E, SAILER N, MOUMTZOUOGLOU A, et al.Visfatin(nampt)and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes[J]. Exp Clin Endocrinol Diabetes, 2010, 118(2):75-80.

[31] MARTINEZL M T, CORBATON A A, FERNANDEZ P C, et al.Obesity and cardiovascular risk:variations in visfatin gene can modify the obesity associated cardiovascular risk results from the Segovia population based-study[J]. Plos One, 2016, 11(5):e0153976.

[32]俞力,施良,戴莉敏,等.内脂素基因启动子多态性与中国人2型糖尿病脂代谢紊乱的相关性[J].中国老年学杂志, 2010, 30(22):3250-3252.

[33]饶进,王刚,何皓,等.内脂素基因rs2058539位点多态性与血脂水平及冠心病易感性的关联研究.临床内科杂志. 2014,31(7):454-456.